Topics

MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors

13:26 EDT 28 Oct 2019 | OncLive

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.

Original Article: MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...